|
|
Post by saxcmann on Sept 10, 2016 18:35:39 GMT -5
This weekend endos are taking continuing education courses in Cleveland and Seattle. My friend is in Cleveland for his boards review. 2 slides came up from a presenter on afrezza. 1st slide showed dreamboat. The 2nd slide was from an old study in 2010 by MNKD! The scientific data was over 6 years ago and not current. He was using old PK PD data. Showed worse glucose action same as biaspart insulin. Time action of 120 mins. The presenter said afrezza unlikely to have benefits over current therapy. He really didn't know what he was talking about my friend said!! It's prob not his fault only. It's a lack of education at the highest levels of endo specialty. Pathetic and scary really!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 10, 2016 20:10:03 GMT -5
One would think someone from MannKind would have input on training presented to endos? Or am I missing something?
|
|
|
|
Post by sportsrancho on Sept 10, 2016 20:21:59 GMT -5
Thank you sax, I'm speechless! Unbelievable.
|
|
|
|
Post by kc on Sept 10, 2016 20:28:48 GMT -5
If you get me the information of the meeting and group we can email to Mike C. He is very responsive about follow up. Training in this field and for that matter most industries are dated. So we shouldn't be alarmed but do need to forward to management so they can work behind the scenes to educate professionals who should know what they are presenting.
|
|
|
|
Post by bioexec25 on Sept 10, 2016 20:32:38 GMT -5
Hard to believe there's no mechanism to keep "continuing ed" decks more current & standard. Depressing state of affairs if this a deck by deck correction of the facts. No wonder big pharma wins up until the very second that they don't.
|
|
|
|
Post by od on Sept 10, 2016 21:36:43 GMT -5
If you get me the information of the meeting and group we can email to Mike C. He is very responsive about follow up. Training in this field and for that matter most industries are dated. So we shouldn't be alarmed but do need to forward to management so they can work behind the scenes to educate professionals who should know what they are presenting. Based on what Saxcmann shared, I believe you will find the information at www.endocrine.org/ebr/program |
|
|
|
Post by od on Sept 10, 2016 21:37:56 GMT -5
Hard to believe there's no mechanism to keep "continuing ed" decks more current & standard. Depressing state of affairs if this a deck by deck correction of the facts. No wonder big pharma wins up until the very second that they don't. "No wonder big pharma wins up until the very second that they don't." p Please explain. Thanks. |
|
|
|
Post by kc on Sept 10, 2016 23:43:13 GMT -5
If you get me the information of the meeting and group we can email to Mike C. He is very responsive about follow up. Training in this field and for that matter most industries are dated. So we shouldn't be alarmed but do need to forward to management so they can work behind the scenes to educate professionals who should know what they are presenting. Based on what Saxcmann shared, I believe you will find the information at www.endocrine.org/ebr/programOD Sax said it was the Cleveland program. This was from the Seattle program. I could not densify on it. Perhaps he can get his friend to send it to him and I will send it on to MannKind |
|
|
|
Post by kc on Sept 10, 2016 23:44:05 GMT -5
This weekend endos are taking continuing education courses in Cleveland and Seattle. My friend is in Cleveland for his boards review. 2 slides came up from a presenter on afrezza. 1st slide showed dreamboat. The 2nd slide was from an old study in 2010 by MNKD! The scientific data was over 6 years ago and not current. He was using old PK PD data. Showed worse glucose action same as biaspart insulin. Time action of 120 mins. The presenter said afrezza unlikely to have benefits over current therapy. He really didn't know what he was talking about my friend said!! It's prob not his fault only. It's a lack of education at the highest levels of endo specialty. Pathetic and scary really! Can you get the information from your friend taking his boards. |
|
|
|
Post by lakon on Sept 11, 2016 6:32:35 GMT -5
Hard to believe there's no mechanism to keep "continuing ed" decks more current & standard. Depressing state of affairs if this a deck by deck correction of the facts. No wonder big pharma wins up until the very second that they don't. The "Dark Ages" was about keeping people in the Dark. It never died for much of the world. Some wish to return us there more quickly than others, but they are all our enemy just the same... |
|
|
|
Post by saxcmann on Sept 11, 2016 8:34:57 GMT -5
This weekend endos are taking continuing education courses in Cleveland and Seattle. My friend is in Cleveland for his boards review. 2 slides came up from a presenter on afrezza. 1st slide showed dreamboat. The 2nd slide was from an old study in 2010 by MNKD! The scientific data was over 6 years ago and not current. He was using old PK PD data. Showed worse glucose action same as biaspart insulin. Time action of 120 mins. The presenter said afrezza unlikely to have benefits over current therapy. He really didn't know what he was talking about my friend said!! It's prob not his fault only. It's a lack of education at the highest levels of endo specialty. Pathetic and scary really! Can you get the information from your friend taking his boards. Good morning! Yes, I'll see what I can do. |
|
|
|
Post by saxcmann on Sept 11, 2016 9:07:43 GMT -5
Intensive review of endocrinologist and metabolism. September 8-11. Cleveland Clinic.
|
|
|
|
Post by od on Sept 11, 2016 9:43:35 GMT -5
|
|
|
|
Post by jonny80s on Sept 11, 2016 11:10:19 GMT -5
What we should ask ourselves is why didn't Mannkind have a presence at these venues if these are the prescribers that Mannkind's sales force are supposed to be targeting?
Seems a little absurd.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 11, 2016 11:19:04 GMT -5
It's board review series training. Depends on the course material and the person who prepared it. Its intention is to clear the boards
|
|
